

**IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF WEST VIRGINIA
AT CLARKSBURG**

REGENERON PHARMACEUTICALS, INC.,

Plaintiff,

v.

MYLAN PHARMACEUTICALS INC.,

Defendant.

Case No. 1:22-cv-00061-TSK

CONFIDENTIAL:

FILED UNDER SEAL

**DEFENDANT MYLAN PHARMACEUTICALS INC.'S
RESPONSIVE CLAIM CONSTRUCTION BRIEF**

TABLE OF CONTENTS

I. INTRODUCTION. 1

II. RESPONSIVE ARGUMENT: The 865 Patent Claim Terms. 2

A. “Organic Co-Solvent” 2

1. Regeneron fails to assist the Court in construing the claim term. 3

2. Neither the claims nor the specification establishes that the “organic co-solvent” is polysorbate. 4

3. Regeneron misstates the parties’ dispute and Mylan’s construction. 6

B. “[Present In] Native Conformation.” 8

1. Regeneron’s non-construction reflects legal error and fails its burden. 8

2. The “as measured by size exclusion chromatography” limitation is indefinite and superfluous under Regeneron’s proposal. 9

3. Mylan’s proposal is grounded in the intrinsic evidence. 10

III. RESPONSIVE ARGUMENT: The Dosing Patents Claim Terms. 11

A. Regeneron’s demand to take patients out of the clinical trial context converts its claim language into superfluous statements of intended effect. 11

B. “Best Corrected Visual Acuity” (BCVA). 13

C. “Wherein Exclusion Criteria For The Patient Include” (“Exclusion Criteria”). 18

1. The “exclusion criteria” are unpatentable printed matter. 18

2. The intrinsic evidence confirms the clinical trial context. 20

IV. RESPONSIVE ARGUMENT: The Tustian Patents Claim Terms. 21

A. “Chemically Defined Medium (CDM)” 21

1. The specification definition excludes extracts (i.e. hydrolysates). 21

2. The specification and 635 provisional application are consistent. 22

3. Hydrolysate is not an individual plant-derived component. 23

B.	“Clarified Harvest of Cells/Harvested From a Host Cell Cultured in a [CDM]”	24
1.	“Comprising” cannot be used to eviscerate other express claim terms.....	24
2.	The claims themselves make clear that the cell culture occurs in CDM.	26
3.	Regeneron’s attempt to expand claim scope should be rejected.....	28
C.	“Anti-Oxidants” And “Formulated As An Isotonic Solution”	30
V.	CONCLUSION.....	30

TABLE OF AUTHORITIES

Cases

Amazon.com, Inc. v. Barnesandnoble.com, Inc.,
239 F.3d 1343 (Fed. Cir. 2001) 1, 3

AstraZeneca LP v. Apotex, Inc.,
633 F.3d 1042 (Fed. Cir. 2010) 19

Avid Tech., Inc. v. Harmonic, Inc.,
812 F.3d 1040 (Fed. Cir. 2016) 3

Bard Peripheral Vascular, Inc. v. AngioDynamics, Inc.,
No. 15-218, 2019 WL 1996022 (D. Del. Feb. 11, 2019)..... 20

Baxter Healthcare Corp. v. Mylan Lab ’ys Ltd.,
346 F. Supp. 3d 643 (D.N.J. 2016) 2

Bristol-Myers Squibb Co. v. Ben Venue Lab ’ys, Inc.,
246 F.3d 1368 (Fed. Cir. 2001) passim

Chef Am., Inc. v. Lamb-Weston, Inc.,
358 F.3d 1371 (Fed. Cir. 2004) 15

CIAS, Inc. v. All. Gaming Corp.,
504 F.3d 1356 (Fed. Cir. 2007) 4

Cont’l Circuits LLC v. Intel Corp.,
915 F.3d 788 (Fed. Cir. 2019) 5

Dippin’ Dots, Inc. v. Mosey,
476 F.3d 1337 (Fed. Cir. 2007) 25, 29

Embrex, Inc. v. Serv. Eng’g Corp.,
216 F.3d 1343 (Fed. Cir. 2000) 25, 28

Finjan LLC v. ESET, LLC,
51 F.4th 1377 (Fed. Cir. 2022) 22

Hill-Rom Servs., Inc. v. Stryker Corp.,
755 F.3d 1367 (Fed. Cir. 2014) 5

Housey Pharms., Inc. v. AstraZeneca UK Ltd.,
366 F.3d 1348 (Fed. Cir. 2004) 2, 6, 8, 10

In re Ngai,
367 F.3d 1336 (Fed. Cir. 2004) 19

In re: Copaxone Consol. Cases,
 906 F.3d 1013 (Fed. Cir. 2018) passim

Intellectual Ventures I LLC v. T-Mobile USA, Inc.,
 902 F.3d 1372 (Fed. Cir. 2018) 5, 8

Invitrogen Corp. v. Biocrest Mfg., LP,
 327 F.3d 1364 (Fed. Cir. 2003) 29

King Pharms., Inc. v. Eon Labs, Inc.,
 616 F.3d 1267 (Fed. Cir. 2010) 18, 19

Liebel-Flarsheim Co. v. Medrad, Inc.
 358 F.3d 898 (Fed. Cir. 2004) 5

Minton v. Nat’l Ass’n of Sec. Dealers, Inc.,
 336 F.3d 1373 (Fed. Cir. 2003) 13

Moore U.S.A. Inc. v. Standard Reg. Co.,
 2000 WL 876884 (W.D.N.Y. May 26, 2000)..... 1

NeoMagic Corp. v. Trident Microsystems, Inc.,
 287 F.3d 1062 (Fed. Cir. 2002) 3

Novartis Pharms. Corp. v. Abbott Lab’ys,
 375 F.3d 1328 (Fed. Cir. 2004) 6, 7

Nuvo Pharm. (Ireland) Designated Activity Co. v. Dr. Reddy’s Labs. Inc.,
 923 F.3d 1368 (Fed. Cir. 2019) 4, 9

On Demand Mach. Corp. v. Ingram Indus.,
 442 F.3d 1331 (Fed. Cir. 2006) 4, 13

Ortho-McNeil Pharm., Inc. v. Mylan Lab’ys, Inc.,
 520 F.3d 1358 (Fed. Cir. 2008) 15

Phillips v. AWH Corp.,
 415 F.3d at 1303 (Fed. Cir. 2005)..... 2, 4

Power Integrations, Inc. v. Fairchild Semiconductor Int’l, Inc.,
 843 F.3d 1315 (Fed. Cir. 2016) 15

Power Mosfet Techs., LLC v. Siemens AG,
 378 F.3d 1396 (Fed. Cir. 2004) 25

PPG Indus. v. Guardian Indus. Corp.,
 156 F.3d 1351 (Fed. Cir. 1998) 4

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.